Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Status:
Recruiting
Trial end date:
2032-05-01
Target enrollment:
Participant gender:
Summary
The main aim is to identify and describe biomarkers in different sample types related to
chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive
non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation.
The hypothesis is that clinical differences in course of disease reflect underlying
biological characteristics.